NCT06562192 - Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers | Biotech Hunter

Enrollment

124

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

June 25, 2030

Study Completion Date

June 26, 2030

Conditions

Pancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerHR+/HER2- Ductal and Lobular Breast CancerTriple Negative Breast CancerColorectal Cancer

Interventions

DRUG

[68Ga]Ga-NNS309

Radioligand imaging agent

DRUG

[177Lu]Lu-NNS309

Radioligand therapy

Trial Locations (21)

1000

RECRUITING

Novartis Investigative Site, Brussels

20133

RECRUITING

Novartis Investigative Site, Milan

28040

RECRUITING

Novartis Investigative Site, Madrid

42123

RECRUITING

Novartis Investigative Site, Reggio Emilia

49503

RECRUITING

BAMF Health, Grand Rapids

RECRUITING

BAMF Health, Grand Rapids

55905

RECRUITING

Mayo Clinic Rochester, Rochester

69677

RECRUITING

Novartis Investigative Site, Bron

77030

RECRUITING

Uni Of TX MD Anderson Cancer Cntr, Houston

90095

RECRUITING

University of California LA, Los Angeles

94304

RECRUITING

Stanford University Medical Center, Palo Alto

94800

RECRUITING

Novartis Investigative Site, Villejuif

98109

RECRUITING

University Of Washington, Seattle

6423906

RECRUITING

Novartis Investigative Site, Tel Aviv

02114

RECRUITING

Massachusetts General Hospital, Boston

M5G 2M9

RECRUITING

Novartis Investigative Site, Toronto

H2W 1T8

RECRUITING

Novartis Investigative Site, Montreal

H3T 1E2

RECRUITING

Novartis Investigative Site, Montreal

3584 CX

RECRUITING

Novartis Investigative Site, Utrecht

08036

RECRUITING

Novartis Investigative Site, Barcelona

CH 1211

RECRUITING

Novartis Investigative Site, Geneva